公开(公告)号：US20250041298A1

公开(公告)日：2025-02-06

申请号：US18714642

申请日：2022-11-29

Applicant: Pfizer Inc. ,  PFIZER INC.

Inventor： Tun Tun Lin ,  Jing Yang

IPC: A61K31/506 ,  A61K31/4196 ,  A61K31/565 ,  A61P35/00

Abstract: The disclosure provides a method of treating cancer comprising administering to a subject in need thereof with a therapeutically effective amount of PF-07220060. The disclosure also provides a method of treating cancer comprising administering to a subject in need thereof with a therapeutically effective amount of PF-07220060 and an endocrine therapy agent.

公开(公告)号：US5268453A

公开(公告)日：1993-12-07

申请号：US918953

申请日：1992-07-30

Applicant: Robin J. Andy ,  Eric R. Larson

Inventor： Robin J. Andy ,  Eric R. Larson

IPC: A61K38/00 ,  C07K14/62 ,  C07K7/00 ,  A61K37/26 ,  C12P21/06

CPC classification number: C07K14/62 ,  A61K38/00 ,  Y10S514/866

Abstract: Human insulin analogs are disclosed. These analogs are tissue-selective. Accordingly, pharmaceutical formulations containing the analogs of the invention provide superior clinical benefits as compared to human insulin when used in the treatment of patients suffering from diabetes. The analogs are modified at amino residue A12, A15 or A19, are different from the naturally occurring residue at said position, and are hepatoselective. Also disclosed are human insulin analogs modified at amino acid residues A12 or A14 or amino acid residues A10 and A13 different from naturally occurring residues or residues at said position or positions and are peripheral selective. DNA sequences and microorganisms comprising sequences coding for human insulin analogs are also provided. Processes for preparing the human insulin analogs are described.

Abstract translation: 人胰岛素类似物被公开。 这些类似物是组织选择性的。 因此，当用于治疗患有糖尿病的患者时，与人胰岛素相比，含有本发明类似物的药物制剂提供了优异的临床益处。 类似物在氨基残基A12，A15或A19处被修饰，与所述位置处的天然存在的残基不同，并且是肝选择性的。 还公开了在氨基酸残基A12或A14处修饰的人胰岛素类似物或在所述位置或位置处与天然存在的残基或残基不同的氨基酸残基A10和A13，并且是周边选择性的。 还提供了包含编码人胰岛素类似物的序列的DNA序列和微生物。 描述了制备人胰岛素类似物的方法。

公开(公告)号：US20250163125A1

公开(公告)日：2025-05-22

申请号：US18826540

申请日：2024-09-06

Applicant: PFIZER INC. ,  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： Natasha Kay CRELLIN ,  Lauren Kate ELY ,  Jason Robles REYES ,  Chia Chi HO ,  Jeffrey A. BLUESTONE ,  Eleonora TROTTA ,  Qizhi TANG

IPC: C07K14/705 ,  A61K39/00 ,  C12N15/63 ,  G01N33/50 ,  G01N33/68

Abstract: The invention provides LFA3 polypeptide molecules, e.g., variant LFA3 fusion polypeptide molecules. The invention includes uses, and associated methods of using the LFA3 polypeptide molecules.

公开(公告)号：US12297190B2

公开(公告)日：2025-05-13

申请号：US17029557

申请日：2020-09-23

Applicant: PFIZER INC.

Inventor： Ryan Patman ,  Martin James Wythes ,  Eugene Yuanjin Rui ,  Indrawan James McAlpine ,  Andrew Fensome ,  Mehran Jalaie ,  Ketan S. Gajiwala ,  Chan Woo Huh ,  Tuan Phong Tran ,  Lei Zhang ,  Dahui Zhou ,  Ethan Lawrence Fisher

IPC: C07D403/14 ,  A61K31/4196 ,  A61K31/424 ,  A61K31/427 ,  A61K31/437 ,  A61K31/454 ,  A61K31/5377 ,  A61K31/5386 ,  A61K38/21 ,  A61K39/395 ,  C07D401/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/06 ,  C07D491/08 ,  C07D491/107 ,  C07D498/04 ,  C07D498/08

Abstract: Compounds of the general formula (I): or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

公开(公告)号：US20250127759A1

公开(公告)日：2025-04-24

申请号：US18715080

申请日：2022-12-01

Applicant: PFIZER INC.

Inventor： Jerry LI ,  Tun Tun LIN

IPC: A61K31/4155 ,  A61K31/4196 ,  A61K31/506 ,  A61K31/519 ,  A61K31/565 ,  A61P35/00

Abstract: The disclosure provides methods of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of PF-07104091, as a monotherapy or in combination with an endocrine therapy agent and/or a CDK4/6 inhibitor.

公开(公告)号：US20250114442A1

公开(公告)日：2025-04-10

申请号：US18828443

申请日：2024-09-09

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Laurent Oliver Chorro ,  Robert George Konrad Donald ,  Jacqueline Marie Lypowy ,  Rosalind Pan

IPC: A61K39/108 ,  A61K39/00 ,  A61P31/04 ,  A61P37/04

Abstract: This invention relates to compositions that include a polypeptide derived from E. coli or a fragment thereof; and modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof, and methods of use thereof.

公开(公告)号：US12269896B2

公开(公告)日：2025-04-08

申请号：US17975508

申请日：2022-10-27

Applicant: PFIZER INC.

Inventor： Chew Shun Chang ,  Gurkan Guntas ,  Madan Katragadda ,  Divya Mathur ,  Adam Reid Root ,  Lidia Mosyak ,  Edward Roland Lavallie

IPC: C07K16/40 ,  A61K45/06 ,  A61P35/00

Abstract: The present invention provides novel antibodies that specifically bind to GUCY2c and uses thereof in the treatment of cancer. The present invention further provides novel bispecific antibodies comprising such antibodies and uses thereof in the treatment of cancer.

公开(公告)号：US12268669B2

公开(公告)日：2025-04-08

申请号：US17415902

申请日：2019-12-17

Applicant: Pfizer Inc.

Inventor： Christine Ellen Bulawa ,  James Allan Fleming

IPC: A61K31/423 ,  A61K31/4025 ,  A61K31/4245 ,  A61P25/00 ,  C07K16/18 ,  C12N15/113

Abstract: The present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof a combination of a benzoxazole derivative transthyretin stabilizer or a pharmaceutically acceptable salt or prodrug thereof and an additional therapeutic agent for the treatment of transthyretin amyloidosis. Particularly, the present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or a pharmaceutically acceptable salt or prodrug thereof and one or more additional therapeutic agent for the treatment of transthyretin amyloidosis.

公开(公告)号：US20250064732A1

公开(公告)日：2025-02-27

申请号：US18825795

申请日：2024-09-05

Applicant: PFIZER INC.

Inventor： James Joseph HUSSEY ,  Andrew Gilbert Bright

IPC: A61K9/08 ,  A61K9/00 ,  A61K9/19 ,  A61K31/5377 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  A61K47/40 ,  A61P35/00

Abstract: The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable organic or inorganic acid salt thereof, a pharmaceutically acceptable organic or inorganic acid, a pharmaceutically acceptable beta- or gamma-cyclodextrin and water, that is a clear solution, with the proviso that the organic or inorganic acid (including a salt thereof) is not a sulphonic acid. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.

公开(公告)号：US20250051246A1

公开(公告)日：2025-02-13

申请号：US18799069

申请日：2024-08-09

Applicant: Pfizer Inc.

Inventor： Karen Jean COFFMAN ,  Dafydd Rhys OWEN ,  Matthew Richard REESE ,  Matthew Forrest SAMMONS ,  Raman SHARMA ,  Jamison Bryce TUTTLE ,  Qingyi YANG

IPC: C07B59/00 ,  A61K31/4025 ,  A61P31/14 ,  C07D403/12

Abstract: The invention relates to compounds of Formula (I) wherein Y1a, Y1b, Y2a, Y2b, Y2c, Y2d, Y2e, Y2f, Y2g, Y2h and Y2i are as defined herein and to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may be useful in the treatment of coronavirus infections and coronavirus infection related disorders.